Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Itsuro Nagase"'
Autor:
Kentaro Takeda, Itsuro Nagase, Takashi Seto, Haruyasu Murakami, Sawori Watanabe, Satoshi Morita, Maiko Morishita, Junko Toyoshima, Kazuhiko Nakagawa, Akira Ono, Shigeru Takeshita, Toshio Shimizu, Erkut Bahceci, Masahiro Fukuoka
Publikováno v:
Drugs in R&D
Background and Objective Anaplastic lymphoma kinase gene rearrangements (ALKr) resulting in EML4–ALK proteins occur in a subset of solid tumors and are targeted by ALK inhibitors. Given the development of drug resistance to ALK inhibitors, ALK inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a2aaa9adacd8964f57cf450c3d415e
https://doi.org/10.1007/s40268-020-00331-2
https://doi.org/10.1007/s40268-020-00331-2
Autor:
Itsuro Nagase, Takahashi Takumi, Tatsuya Maruyama, Masahiko Hayakawa, Kenichi Onda, Toshiyuki Takasu, Mitsuaki Ohta, Tetsuo Matsui, Takayuki Suzuki
Publikováno v:
CHEMICAL & PHARMACEUTICAL BULLETIN. 60:647-658
In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential drugs for use in treating obesity and non-insulin dependent (type 2) diabetes, a series of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2390a5b24b25b089cb8b6cd4dcc1cad1
https://doi.org/10.1248/cpb.60.647
https://doi.org/10.1248/cpb.60.647
Autor:
Atsushi Utsuno, Shigeru Kageyama, Shigenori Kawasaki, Takeshi Kadokura, Itsuro Nagase, Satoshi Yoshida, Masako Saito, Kenichi Kazuta
Publikováno v:
Diabetology International. 2:172-182
This phase 1, randomized, placebo-controlled, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ipragliflozin (ASP1941) in healthy Japanese subjects. Subjects received a single oral dose (1–300 mg)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05cd125d328802f710543d56bb730e48
https://doi.org/10.1007/s13340-011-0037-8
https://doi.org/10.1007/s13340-011-0037-8
Autor:
Tetsuo Matsui, Hiroyuki Moritomo, Norio Seki, Itsuro Nagase, Tatsuya Maruyama, Toshiyuki Takasu, Masahiko Hayakawa, Kenichi Onda, Takahashi Takumi, Mitsuaki Ohta, Takayuki Suzuki
Publikováno v:
Bioorganic & Medicinal Chemistry. 17:3283-3294
In the search for potent and selective human beta3-adrenergic receptor (AR) agonists as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes, a novel series of phenoxypropanolamine derivatives containing acetanilid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4e8c5ba8d547f110e1b4e0b1ab9642
https://doi.org/10.1016/j.bmc.2009.03.044
https://doi.org/10.1016/j.bmc.2009.03.044
Autor:
Masayuki Shibasaki, Yuka Someya, Akiko Matsuyama-Yokono, Itsuro Nagase, Atsuo Tahara, Ryosuke Nakano, Masahiko Hayakawa
Publikováno v:
Biochemical Pharmacology. 76:98-107
Dipeptidyl peptidase (DPP)-IV inhibitors are expected to become a useful new class of antidiabetic agent. The aim of the present study is to characterize the in vitro and in vivo profile of ASP8497, (2S,4S)-4-fluoro-1-({[4-methyl-1-(methylsulfonyl)pi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc6be8e7ee9e1d9041a736437f7dbed
https://doi.org/10.1016/j.bcp.2008.03.021
https://doi.org/10.1016/j.bcp.2008.03.021
Autor:
Kenzo Kumamoto, Motoharu Kondo, Naoki Sakane, Toshihide Yoshida, Teruo Kawada, Masayuki Saito, Tsunekazu Umekawa, Itsuro Nagase, Akinori Kogure, Yasuo Wakabayashi
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 274:E469-E475
The mitochondrial uncoupling protein (UCP) has usually been found only in brown adipose tissue. We recently observed that a chronic administration of the β3-adrenergic agonist CL-316,243 (CL) induced the ectopic expression of UCP in white fat and sk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06fdaa3ec98d61e973b0af54ff7b12f9
https://doi.org/10.1152/ajpendo.1998.274.3.e469
https://doi.org/10.1152/ajpendo.1998.274.3.e469
Autor:
Shigeru Kageyama, Satoshi Yoshida, Itsuro Nagase, Atsushi Utsuno, Ronald A. Smulders, Noriko Akiyama, Atsunori Kashiwagi, Kenichi Kazuta, Takeshi Kadokura
Publikováno v:
Diabetes research and clinical practice. 106(1)
Aims Ipragliflozin is a novel and highly selective sodium–glucose transporter 2 (SGLT2) inhibitor that reduces plasma glucose levels by enhancing urinary glucose excretion in patients with type 2 diabetes mellitus (T2DM). We examined the pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b402f59d9fa58bba73dffb46d65c5106
https://pubmed.ncbi.nlm.nih.gov/25149596
https://pubmed.ncbi.nlm.nih.gov/25149596
Publikováno v:
Journal of Diabetes Investigation
Aims/Introduction In the present dose–response study, we evaluated the efficacy and safety of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose cotransporter 2, in Japanese patients with type 2 diabetes mellitus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c21fe6f8f58e628814cfb379d9ba5ba
https://pubmed.ncbi.nlm.nih.gov/25411597
https://pubmed.ncbi.nlm.nih.gov/25411597
Autor:
Toshihide Yoshida, Itsuro Nagase, T Umekawa, H Nikami, N Sakane, K Kumamoto, Masayuki Saito, Teruo Kawada
Publikováno v:
Journal of Clinical Investigation. 97:2898-2904
The mitochondrial uncoupling protein (UCP) is usually expressed only in brown adipose tissue (BAT) and a key molecule for metabolic thermogenesis. The effects of a highly selective beta 3-adrenergic agonist, CL316,243 (CL), on UCP expression in skele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c8739379d7c0803df4d2873744debd
https://doi.org/10.1172/jci118748
https://doi.org/10.1172/jci118748
Autor:
Charles Liu, Takeshi Kadokura, Jessica K. Altman, Alexander E. Perl, Catherine C. Smith, Geoffrey Yuen, Angela Joubert James, Peter L. Bonate, Erkut Bahceci, Itsuro Nagase, Ogert Fisniku, Mark J. Levis, Mark R. Litzow, Stan Gill
Publikováno v:
Journal of Clinical Oncology. 34:7026-7026
7026Background: Gilteritinib, also known as ASP2215, is a selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML). In ongoing trials, gilteritinib has demonstrated...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2309647984cefb40187e8cf6257e1c80
https://doi.org/10.1200/jco.2016.34.15_suppl.7026
https://doi.org/10.1200/jco.2016.34.15_suppl.7026